Skip to product information
1 of 1

  • Images are for illustration purposes only
  • Gphc Registered
  • Join over 100k customers
  • Fixed prices and no subscriptions
  • Discreet next day delivery.
  • Free shipping on all orders over £50

Avene Very High Protection Spray SPF50+200ml

Avene Very High Protection Spray SPF50+200ml

  • 1. Ozempic®️-equivalent therapy now available for weight management
  • 2. Average weight loss of 17%, with 1 in 3 patients achieving over 20%
  • 3. May help reduce osteoarthritis-related pain
  • 4. Wegovy®️ is not expected to impact the effectiveness of oral contraceptives
  • 5. Supports cardiovascular risk reduction
  • 6. Over 22 million patients treated with semaglutide-based therapies since 2018

We’re proud to offer fast and discreet delivery for all our medicines & treatments.

Price Checker

Regular price £24.00
Sale price £24.00
Sale Sold out
  • Lowest price guarantee
  • Includes FREE private prescription
View full details

Avene Very High Protection Spray SPF50+ 200ml

Product Description: Avene Very High Protection Spray SPF50+ 200ml is a sunscreen spray that provides very high sun protection against UVA and UVB rays.

How to Use:

  • Shake well before use.
  • Spray evenly onto the skin before sun exposure.
  • Reapply frequently, especially after swimming or sweating.

Directions:

  • For best results, apply the sunscreen 30 minutes before sun exposure.
  • Reapply every 2 hours, or more often if swimming or sweating heavily.

Side Effects:

  • Mild tingling or burning sensation.
  • Skin irritation or redness.
  • If any severe reactions occur, discontinue use and consult a healthcare professional.

Warnings:

  • Avoid prolonged sun exposure, even while using a sunscreen product.
  • Avoid spraying directly on the face; spray into hands and then apply to the face.
  • Avoid contact with eyes. In case of contact, rinse thoroughly with water.

Storage Information:

  • Store in a cool, dry place away from direct sunlight.
  • Keep out of reach of children.

Customer Reviews

Be the first to write a review
0%
(0)
0%
(0)
0%
(0)
0%
(0)
0%
(0)

Patient Information Leaflet

Important - Before taking any medication, it is always important to read the Patient Information Leaflet (PIL)

Written and reviewed by our qualified team

GPhC Number: 2233073
Tarun Kumar

Reviewed by:

Tarun Kumar

Superintendent/ Clinical Lead

📖 Find out more about our team of medical content authors and how we ensure the accuracy of our content with our content guidelines.

Content last updated: 31 Mar 2025

We’re a safe and
regulated UK service

Registered Pharmacy Badge

Lowest Price Guarantee

We're convinced you won't find your treatment cheaper, but if you do we'll refund the difference.

Find out more

100% discreet packaging

We're convinced you won't find your treatment cheaper, but if you do we'll refund the difference.

Find out more

Agent

Need help?
Talk to our friendly experts now

How our service works

Service Setup

Service setup

Discreet Packaging

Discreet packaging

Express Delivery

Express delivery

Comparison of Weight Loss Injectables

Features

Mounjaro®

Injectable Pen

Wegovy®

Injectable Pen

Saxenda®

Injectable Pen

Active Ingredient Tirzepatide Semaglutide Liraglutide
Mechanism of Action GLP-1 and GIP receptor agonist GLP-1 receptor agonist GLP-1 receptor agonist
Administration Weekly injection Weekly injection Daily injection
Dosage Varies by patient, typically starting low Varies, typically starting at 0.25 mg Varies, starting at 0.6 mg
Effect on Appetite Significantly reduces appetite and cravings Reduces appetite and increases satiety Reduces appetite and increases satiety
Average Weight Loss Up to 20% body weight reduction Up to 15% body weight reduction Significant weight reduction
Side Effects Nausea, vomiting, diarrhoea, constipation Nausea, vomiting, diarrhoea, constipation Nausea, diarrhoea, constipation, hypoglycemia
Approval FDA-approved for weight loss FDA-approved for weight loss FDA-approved for weight loss
Suitable For Adults with BMI ≥30 or ≥27 with comorbidities Adults with BMI ≥30 or ≥27 with comorbidities Adults with BMI ≥30 or ≥27 with comorbidities